In a recent update, Bank of America analyst Tazeen Ahmad adjusted the price target for Argenx (ARGX, Financial), bringing it down to EUR 680 from the previous EUR 736. Despite this revision, the Buy rating on the shares has been maintained. The adjustment is part of the firm's broader updates in the small-to-mid-cap biotech sector as it prepares for the first quarter earnings reports.
Argenx continues to hold a significant position in the analyst's top picks for 2025, signaling ongoing confidence in the company's potential despite the revised price target. The company's strategic initiatives and projected growth remain focal points for investors as they anticipate forthcoming financial disclosures.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for argenx SE (ARGX, Financial) is $738.07 with a high estimate of $1,100.00 and a low estimate of $416.00. The average target implies an upside of 23.80% from the current price of $596.20. More detailed estimate data can be found on the argenx SE (ARGX) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, argenx SE's (ARGX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for argenx SE (ARGX, Financial) in one year is $1911.48, suggesting a upside of 220.61% from the current price of $596.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the argenx SE (ARGX) Summary page.
